REPLICor to present at the 19th International Conference on Antiviral Research
Laval, Quebec – May 5th, 2006 – REPLICor announced today that it will be a presenter at the 19th International Conference on Antiviral Research (ICAR) 2006 in San Juan, Puerto Rico. REPLICor as well as several of its collaborators will be making a total of four presentations (two oral and two poster). The seminal presentation on REPLICor’s novel nucleic acid-based antiviral technology will be given by Dr Andrew Vaillant, CSO on May 8th, 2006.
“We are excited to present at ICAR 2006 and to report REPLICor’s development of its technology as a broad-spectrum antiviral agent in HIV, influenza, RSV and Herpesviridae ” commented Dr Vaillant. “ICAR is one of the most important antiviral conferences in the World and we are proud to be one of the presenting companies” he added.
About ICAR
ICAR is an annual meeting of the International Society for Antiviral Research (ISAR). This meeting is an opportunity for both academia as well as industry to meet to see new updates on the latest antiviral technologies both in preclinical and clinical development.
About REPLICor
REPLICor Inc. is a biopharmaceutical company developing novel broad-spectrum antiviral drugs. Its lead compound, REP 9, is active against 12 viral families including influenza, hepatitis B and C, HIV, RSV and herpes. The company’s business strategy is to enter into an alliance with a major pharmaceutical company to further develop and market its technology.
For more information:
Andrew Vaillant PhD, CSO
REPLICor Inc.
450 688 6068